Skeletal muscle fibers form in overlapping, but distinct phases that depend on the generation of temporally different lineages of myogenic cells. During primary myogenesis (E10.5-E12.5 in the mouse), embryonic myoblasts fuse homotypically to generate primary fibers, whereas during later development (E14.5-E17.5), fetal myoblasts differentiate into secondary fibers. How these myogenic waves are regulated remains largely unknown. Studies have been hampered by the lack of markers which would distinguish embryonic from fetal myoblast populations. We show here that the homeobox gene Arx is strongly expressed in differentiating embryonic muscle, downstream of myogenic basic helix-loop-helix (bHLH) genes. Its expression progressively decreases during development. When overexpressed in the C2C12 myogenic cell line, Arx enhances differentiation. Accordingly, it stimulates the transcriptional activity from the Myogenin promoter and from multimerized E-boxes when co-expressed with MyoD and Mef2C in CH310T1/2. Furthermore, Arx co-immunoprecipitates with Mef2C, suggesting that it participates in the transcriptional regulatory network acting in embryonic muscle. Finally, embryonic myoblasts isolated from Arx-deficient embryos show a delayed differentiation in vivo together with an enhanced clonogenic capacity in vitro. We propose here that Arx acts as a novel positive regulator of embryonic myogenesis by synergizing with Mef2C and MyoD and by establishing an activating loop with Myogenin.
In amniotes, skeletal muscle differentiates in successive steps involving different type of myogenic progenitors. 1 At about E11 in the mouse, during a phase usually referred to as primary myogenesis, embryonic myoblasts invade the limb buds and the pre-existing myotome, which is comprised of mononucleated differentiated myocytes, and fuse to form myotubes. These are the first multinucleated fibers that appear in the embryo and are termed 'primary' fibers. A second wave of myogenesis (secondary myogenesis) takes place between E14.5 and E17.5 and involves fusion of fetal myoblasts. At the end of gestation (after E16.5), emerging satellite cells can be identified as mononucleated cells located between the basal lamina and the fiber plasma membrane. 2 Satellite cells are thought to be responsible for the postnatal growth and regeneration of the muscles. Work of several laboratories identified specific features of the different type of myoblasts. In particular, we recently reported that embryonic myoblasts have a greater propensity to differentiate compared to their fetal counterparts, since they more readily express markers of differentiation, have reduced proliferation and clonogenic ability in vitro. 3 Embryonic, fetal myoblasts and satellite cells derive from a Pax3/Pax7-positive population of myogenic progenitors resident in the dermomyotome. 4, 5 During skeletal muscle development these mesoderm-derived progenitors generate myoblasts, which become postmitotic and then terminally differentiate into multinucleated myotubes. The muscle regulatory factors (MRFs) MyoD, Myf5, Mrf4 and Myogenin 6 are key regulators of the myogenic program and when transfected in fibroblasts, can convert them to a myogenic fate. Myf5, MyoD and Mrf4 can each independently initiate the myogenic program and thus act as myogenic 'determination' genes during primary myogenesis, whereas only Myf5 and MyoD can fulfill this role during secondary myogenesis. 7 Conversely, Myogenin operates downstream of Myf5, MyoD and Mrf4. 8 MRFs bind to E-box consensus sequences in the control regions of muscle-specific genes. 6 Since all MRFs bind E-box motifs, additional transcription factors are required to regulate MRF specificity for particular target genes and to modulate their action. One such factor is MEF2 (Mef2A, Mef2B, Mef2C and Mef2D) that directly interacts with MRFs and synergizes with them. 9 In addition to MEF2, a certain number of genes can modulate the action of the MRFs and thus positively or negatively regulate muscle differentiation. 10 In this work, we investigated the role of the X-linked 11 transcription factor Arx (Aristaless-related homeobox gene) during skeletal muscle development. Arx has been shown to be important for testes, 12 central nervous system 12 and pancreas development. 13 Here, we show that Arx is predominantly expressed in embryonic myoblasts and primary fibers. Arx acts as positive modulator of myogenesis by synergizing with MyoD and Mef2C and establishing an activating loop with Myogenin. We therefore identify Arx as a novel positive regulator of embryonic myoblast differentiation. We propose that Arx is, at least in part, responsible for the accelerated differentiation of embryonic myoblasts.
Results
Developmental regulation of Arx expression in skeletal muscle. Quantitative PCR was performed on purified embryonic, fetal and postnatal myoblast cultures ( Figure 1a ). Arx expression was significantly higher in undifferentiated embryonic myoblasts compared to fetal and postnatal myoblasts (45.2-and 12.7-fold, respectively). Arx expression remained constant during differentiation of the embryonic population. In contrast, an increase in Arx transcription was observed during differentiation of the fetal population although the levels of Arx mRNA remained considerably lower than that in the embryonic population. Arx expression was also quantified on RNA from limbs and somites collected from E11.5 embryos and from fetal (E16.5) and adult limb muscles. As shown in Figure 1b , Arx expression markedly decreased during development.
Arx expression in vivo was also investigated by wholemount in situ hybridization (ISH). At the onset of primary myogenesis (E10-10.5), Arx was expressed in somites in a cranial-caudal gradient, both in the epaxial (dorsal) and hypaxial (ventral) domains of the myotomes. Expression was also detected in the first branchial arch, pancreas, neural tube and telencephalon (Figure 2a ; data not shown). Significantly, Arx expression was not observed in newly formed myotomes at E9.5 (data not shown).
14 At E11.5, Arx expression was apparent in the forming muscle masses of the limbs (Figure 2b ) and at E13 in the intercostal, branchial and extraocular muscles (Figure 2d) .
Immunostaining showed co-localization of Arx protein with myosin heavy chains (MyHCs) in the myotome (Figure 2c , c 0 ). In contrast, Arx was not detected in fetal or adult muscle, probably reflecting a low level of the protein (data not shown). However, a more sensitive analysis using a knock-in mouseexpressing nuclear b-galactosidase under the control of Arx regulatory sequences 13 also revealed expression during later development. At fetal stages, X-Gal-positive nuclei were detected in all skeletal muscles (Figure 2e ). These nuclei represent only a small fraction of the total number of muscle fiber nuclei as evidenced from a comparison of the staining in the Arx nlacZ with Tg:3F-nlacZ-2E fetuses ( Figure 2f , f 0 ). Interestingly, large primary fibers and smaller secondary fibers 15 can be distinguished by the selective expression of Arx in the former, which presumably derive in large part from embryonic myoblasts (Figure 2g , g 0 ). After birth, a marked decrease in Arx expression, as assessed by X-Gal staining, was observed ( Figure 2h , h 0 ) and in adult muscle, expression was mainly restricted to a subset of fibers with the typical morphology of spindle fibers 16 ( Figure 2i , i 0 , j, j 0 ). In contrast to the limb muscles, the diaphragm maintained a relatively wide Arx expression (Figure 2k ). Collectively, these data suggest that Arx is predominantly expressed by embryonic myoblasts and their derivatives (primary fibers). Arx progressively decreases during development, remaining restricted in the adult to a subset of muscles (e.g., diaphragm) and specific fiber types (spindle fibers).
Arx expression depends upon the myogenic program activated by the myogenic determination genes MyoD, Myf5 and Mrf4 in the trunk, but not in the head.. To test whether Arx expression initiates after the acquisition of muscle identity, ISH was carried out on mutant embryos in which the expression of MyoD, Myf5 and Mrf4 is abolished (Myf5 nlacZ/nlacZ (Mrf4):MyoD À/À ). In these mutants, which completely lack skeletal muscle, 7, 17 Arx expression was undetected in the somitic compartment, but was maintained in the pancreas and central nervous system (Figure 3b (Figure 4a , a 0 , b, e, e 0 , f, j, k). The apparent increase in the differentiation of the cells overexpressing hARX was accompanied by increased levels of MLC1/3F and Myogenin, as determined by PCR and western blot (Figure 4l and m) . Moreover, the hARX , using anti-Arx (red), anti-MyHC (green) antibodies and DAPI to stain the nuclei. X-Gal staining of E18.5 Arx nlacZ fetus (e) and diaphragms of Arx nlacZ (f) and Tg:3F-nlacZ-2E (f 0 ) E18.5 fetuses. (g, g 0 ) Co-immunohistochemistry on transverse sections of hind limbs of E16.5 Arx nlacZ fetuses, using anti-b-galactosidase (red), anti-MyHC (green) antibodies and Hoechst to stain the nuclei. Note that nuclear lacZ is expressed in a subset of fibers with large diameter (arrows) and is almost absent in surrounding small fibers (*). X-Gal staining of hind limb (h) and intercostal (h 0 ) muscles of newborn (P7) Arx nlacZ mice and of soleus muscle (i, magnified in i 0 ) and diaphragm (k) of adult Arx þ /nlacZ mice. X-Gal (j) and hematoxylin and eosin (j 0 ) staining of serial transverse sections of soleus muscle of adult Arx þ /nlacZ mice revealed the expression of the reporter gene in spindle muscle fibers. Adult muscle could only be analyzed from Arx þ /nlacZ mice, because mutant Arx nlacZ males die perinatally. 13 Bar, 50 mm. BA, branchial arches; T, telencephalic vesicle; S, somites; first C1, cranial somite; T1, first thoracic somite; FL, forelimb; HL, hind limb; NT, neural tube; TA, tibialis anterior; Qu, quadriceps; G, gastrocnemius; IM, intercostal muscles; TM, temporalis muscle; BM, branchial muscles; R, ribs Figure 4c , d, g, h). However, the hARX overexpressing myotubes were often branched and not aligned as observed in the control cultures ( Figure 4c , d, g, h). Together, these observations suggest that Arx is able to positively modulate differentiation probably by accelerating the early stages of this process.
Arx mutant embryos display delayed myogenesis. To investigate whether Arx is necessary for normal myogenic differentiation, we studied Arx-null mice. These mice die shortly after birth and display retarded growth, probably due to an abnormal pancreas. 13 At the end of gestation (E19.5), no overt anomalies were observed in the growing muscle masses of mutant mice (data not shown) and adult heterozygous Arx þ /nlacZ mice appeared normal, although some were obese. Nevertheless, at E11.5, MyHC þ muscles in the limb anlagen appeared smaller in the mutant embryos ( Figure Arx synergizes with MyoD and Mef2C in the activation of muscle-specific transcription. We then tested the ability of Arx to activate the Myogenin promoter in a chloramphenicol acetyltransferase (CAT) assay performed on CH310T1/2 that do not normally express the gene. When CH310T1/2 were transfected with an ARX-expressing vector, myogenic conversion was not observed (data not shown). However, when transfected with combinations of vectors encoding ARX or MyoD and a CAT reporter vector carrying the 5 0 regulatory region of mouse Myogenin, a synergistic effect of Arx and MyoD was observed with a threefold increase in reporter activity ( Figure 6a ). Since Mef2C is known to modulate positively the myogenic conversion induced by MRFs in transfected fibroblast, 19 we tested the action of Arx in the presence of both exogenous Mef2C and Myod. The results of this experiment showed an ulterior increase (fivefold increase over MyoD alone; Figure 6a ). Thus, Arx synergizes with MyoD in the activation of the Myogenin promoter and the efficiency of this activation is enhanced by increased levels of Mef2C; the ARX vector alone or co-transfected with a Mef2C-expressing plasmid did not significantly increase CAT expression over the basal level. The same assay has also been performed with a reporter construct containing a multimerized E-box, 20 further confirming the strong synergism (4.9-fold over MyoD alone) between the three factors ( Figure 6b ). Under these experimental conditions, the activation of the reporter vector was only barely enhanced when alternatively Arx or Mef2C were co-transfected with MyoD ( Figure 6b) .
Intriguingly, real-time PCR approach showed that Mef2C, like Arx, is more expressed in embryonic myogenic cells in comparison to their fetal counterparts, both before and after differentiation (5.8-and 2.9-fold, respectively; Figure 6c ).
To investigate a possible physical interaction between the Arx , MyoD and Mef2C proteins, C2C12 were transfected with a vector expressing a Myc-tagged GFP-ARX fusion protein.
The tagged protein was then immunoprecipitated with antiMyc antibodies and the immunoprecipitate probed for MyoD on western blot. The results shown in Figure 6d 0 reveal that the exogenous, tagged ARX co-immunoprecipitated with endogenous MyoD. ) antibodies. Collectively, these data suggest that Arx, MyoD and Mef2C proteins are able to participate into the same complex and that Arx could act as co-activator during myogenic differentiation. Nevertheless, since a direct binding between MRFs and Mef2 proteins has been reported, 19 it is possible that Arx directly associate either with MyoD or Mef2C and the other factor co-immunoprecipitate with Arx because the Mef2 proteins interact with MyoD. To address this point, CH310T1/2 (that do not autonomously express MyoD and Mef2C at variance with C2C12) were co-transfected with different combinations of two plasmids expressing alternatively MyoD, Mef2C or Myc-tagged ARX. These experiments confirmed the physical interaction between MyoD and Mef2C ( Figure 6e 00 ) and revealed that, under these conditions, Arx co-immunoprecipitate with Mef2C (Figure 6e 0 ), but not with MyoD (Figure 6e 000 , e 0000 ). Taken together, these data suggest that Mef2C binds both to Arx and MyoD, whereas MyoD and Arx do not directly interact with each other. Arx establishes a positive regulatory loop with Myogenin. MRFs are required for Arx expression in the embryo (shown above) and in CH310T1/2 (data not shown). However, in CH310T1/2, identification of the specific MRF that activates Arx is complicated by the ability to cross-and auto-activate expression from the endogenous loci. 21 To test whether Arx expression could be induced independently by the different MRFs, mouse embryonic fibroblasts (MEFs) were isolated from Myf5 nlacZ/nlacZ (Mrf4):MyoD À/À mice which lack Myf5, Mrf4 and MyoD. These cells were transfected with plasmids encoding MYF5, MyoD, MRF4 or Myogenin and the expression of Arx was assayed by semiquantitative RT-PCR (Figure 7a (Figure 7b, c, d , e, f); however, only when Myf5 and Mrf4 were switched off, the reduction was dramatic suggesting that both genes are required for full activation of Arx. Nevertheless, although strongly delayed, the appearance of Arx transcripts in the absence of Myf5 and Mrf4 (Figure 7f, arrows) indicates that MyoD and possibly Myogenin can eventually activate Arx.
Discussion
The data reported here show that Arx is expressed in mouse embryonic muscles; its expression is dependent upon the myogenic program activated by MyoD, Myf5 and Mrf4 in somitic muscles, but interestingly not in the first branchial arch. Although further studies are required to understand the fate that Arx-expressing cells in the branchial adopt in mice mutant for MyoD, Myf5 and Mrf4, this observation is in agreement with previous findings that reported differences in the head and somitic myogenic programs. 7, 22 During later development, the expression of Arx progressively decreases. Our PCR data are consistent with the pattern of b-galactosidase expression observed in Arx knockin mice and with a microarray analysis performed on purified embryonic and fetal myoblasts. 3 In the adult Arx þ /nlacZ mice, b-galactosidase expression was maintained in spindle fibers of appendicular muscles and in a large proportion of fibers in the diaphragm. Interestingly, it has been proposed that a subset of spindle fibers may originate from embryonic myoblasts. 16 This is supported by the high expression of Arx in both embryonic myoblasts and spindle fibers.
Arx is strongly expressed in proliferating embryonic myoblasts but only weakly in fetal and adult myoblasts, suggesting that it may play different roles in the different myogenic populations. When hARX was overexpressed in C2C12, precocious expression of differentiation markers was observed in conditions that promote proliferation. This mimics the phenotype of embryonic myoblasts, which express high level of endogenous Arx and are particularly prone to differentiate. 3 Conversely, embryonic myoblasts from Arx mutant mice, which do not express Arx, showed a delayed differentiation in vivo together with an enhanced ability to proliferate in vitro. It is likely that other proteins may cooperate with Arx to enhance the differentiation of embryonic myoblasts and it is conceivable that they may also partially compensate for the absence of Arx, which by itself does not prevent the formation of an apparently normal skeletal muscle at fetal Immunoprecipitation with rabbit anti-GFP antibodies was also performed and give similar results (data not shown). Lysates from untransfected CH310T1/2 and from transfected, but not immunoprecipitated C2C12 (Tot) have been used as negative and positive controls, respectively. (e) CH310T1/2 were transfected with Myc-ARX and pMef2C (e 0 ); pEMSV-Myf3 (Myod1) and pMef2C (e 00 ) or pEMSV-Myf3 and Myc-ARX (e 000 , e 0000 ) plasmids and immunoprecipitated with anti-Myc (e 0 , e 0000 ), anti-MyoD (e 00 , e 000 ) antibodies. Western blot indicated that Mef2c can interact with both ARX and MyoD, whereas MyoD and ARX likely do not bind directly to each other. Immunoprecipitations with anti-Mef2C antibodies confirmed the interaction of Mef2C with MyoD and ARX in CH310T1/2 (data not shown). Immunoprecipitations with non-programmed IgGs showed the specificity of the immunoprecipitations. The asterisks indicate two bands corresponding to hypo-(fast-migrating) and hyper-(slow-migrating) phosphorylated forms of MyoD 18 Arx promotes embryonic myogenesis S Biressi et al stage.
Other myogenic regulators such as Mef2C (see Figure 6c ) are also more highly expressed in embryonic compared with fetal and adult myoblasts. Interestingly, neither Mef2C nor Arx are able to induce myogenic conversion in fibroblasts, but they both appear to be able to modulate positively the myogenic program in presence of MRFs (Lassar et al 18 and present work). We show here that Mef2C physically interacts with both Arx and MyoD, and that in transfected CH310T1/2, a strong synergy occurs between the three factors in the activation of the transcription from Myogenin promoter and multimerized E-boxes containing reporter constructs, suggesting a cooperation in the induction of the myogenic program. Interestingly, previous studies demonstrated that E proteins are required for MyoD function and that the level of endogenous E proteins in CH310T1/2 is sufficient to support myogenic conversion. 18 In contrast, when MyoD and Mef2 were tested for their ability to synergize on artificial reporters, they also required exogenous E12, 19 suggesting that E proteins are limiting for activation of exogenous reporter genes that are rather present at high copy number. The data reported here indicate that forced expression of ARX can somehow substitute for the absence of additional (exogenous) E proteins. Taken together, these observations favor a model in which MyoD, Mef2C and Arx create a multiprotein complex that interacts with the transcriptional machinery more efficiently than any of the individual factors.
Although Arx contains a homeobox DNA-binding domain, 23 it is currently unknown whether its interaction with the Myogenin promoter is direct, mediated or stabilized by other factors. Moreover, as Arx appears to interact physically with Mef2C, but not directly with MyoD, the ability shown by Arx to activate to a certain extent the Myogenin promoter in CH310T1/2 in absence of exogenous Mef2C suggests that Mef2C may be induced by MyoD 24 or that other factors participate in the activation. Arx has been suggested to be a bifunctional transcription factor, capable of functioning either as a repressor 25, 26 or an activator of transcription. 27 The observations reported here suggest that in the context of embryonic myogenesis, Arx positively modulates transcription. The synergism between Arx, Mef2C and MyoD could result from a specific recognition event between the multiprotein complex and a component of the transcriptional machinery or it could result from a concerted reaction in which the assembly of the three factors stabilizes a transcriptional complex, similarly to what was reported for MyoD and Pbx, the latter containing a homeodomain like Arx. 28 The data presented here also show that Arx and Myogenin can upregulate each other's expression. Similarly, Mef2 gene products also regulate Myogenin expression 9, 29 and the Mef2 genes are known targets of the myogenic basic helix-loophelix (bHLH) (24) . It is therefore likely that Arx, probably by coactivating MyoD and Mef2C, enhances the transcriptional circuitry that regulates progression in the lineage to differentiation. In particular, the higher levels of Arx (and Mef2C) present in embryonic myoblasts may contribute to the enhanced differentiation ability that characterizes this myogenic lineage. MyoD, Myf5, Mrf4 and Myogenin appear to play different roles in regulating Arx expression. Myogenin establishes a positive regulatory loop with Arx, which is independent of the other MRFs in MyoD/Myf5/Mrf4-null fibroblasts. Both in vitro and in vivo data suggest that the other MRFs can also activate the expression of Arx albeit with a different efficiency. Differential trans-activation of muscle-specific genes by different MRFs has already been reported. 30 When fibroblasts were transfected with MRFs-encoding plasmids, Arx expression was only induced upon myogenic differentiation (i.e., grown in low serum). In this respect, fibroblasts converted to a myogenic fate by forced MRF expression differ from embryonic myoblasts which are the only cells expressing Arx during proliferation, suggesting the existence of additional factors specific to these cells. Microarray analysis showed that embryonic and fetal myoblasts express similar level of all four MRFs. 3 Therefore, although Arx expression depends on Myf5, Mrf4 and MyoD, other still not identified proteins must be responsible for the enhanced expression of Arx in embryonic myoblasts.
In conclusion, the data presented are the first demonstration that a homeodomain gene differentially regulates embryonic versus fetal myoblast differentiation. Arx activity involves cooperation with MyoD and Mef2C, both of which are also highly expressed in embryonic myoblasts. Moreover, Arx establishes a positive regulatory loop with Myogenin that enhances the transcriptional circuitry regulating differentiation (Figure 8 ).
Materials and Methods
Cell isolation. Embryonic and fetal myoblasts were isolated respectively from E11.5 and E16.5 Myf5 GFPÀP/ þ mice 7 (after removal of the head, internal organs and skin). Tissues were dissociated with 0.15 mg/ml Collagenase Type V (Sigma, St. Louis, Mo, USA), 0.4 mg/ml Dispase (Gibco-Invitrogen, Carlsbad, CA, USA), 0.1 mg/ml DNase I (Roche, Mannheim, Germany). When GFP-expressing cells were isolated from Pax3 GFP/ þ 5 E11.5 embryos, the neural tube and dorsal root ganglia were removed. The lack of any neural crest contamination was confirmed by the absence of Sox10-positive cells in the sorted population (data not shown). GFPexpressing cells were sorted using a Vantage Sorter SE (BD, San Diego, CA, USA). Forward (FSC) and Side Scatter (SSC) parameters were used to gate out cell clumps and debris. Cells dissociated from wt littermates were used to set the gating to exclude green autofluorescence.
Satellite cells were isolated from 3-to 5-day-old mice as described previously.
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Cells were grown at clonal density in DMEM-high glucose supplemented with 20% fetal calf serum (FCS; BioWhittaker-Cambrex, Verviers, Belgium), 20 mM HEPES and 3% chicken embryo. Clones of spindle-shaped satellite cells were trypsinized in cloning cylinders (Sigma) and pooled together. The resulting satellite cell population was 95% pure as assayed by staining with anti-desmin antibody.
Cell culture. To assay colony-forming capacity, unsorted cell suspensions from dissociated wt or Arx-mutant 13 E11.5 and E16.5 mice were plated at clonal density (approximately 200 cells/cm 2 ) and cultured in DMEM-high glucose supplemented with 20% horse serum (BioWhittaker-Cambrex), 20 mM HEPES and 3% chicken embryo extract for 3 days. The myogenic colonies were identified with anti-MyoD antibody.
C2C12 myoblasts were plated at 20 000 cells/cm 2 in DMEM-high glucose, supplemented with 10% FCS. The day after plating, cells were either processed as proliferating cultures, or the medium was replaced with DMEM-high glucose supplemented with 2% FCS to induce differentiation.
Immunofluorescent and b-galactosidase staining of cultured cell and tissue sections. Cell cultures and 8-mm cryostat sections were fixed in 4% paraformaldehyde for 10 min at 41C. For b-galactosidase, staining sections were incubated at 371C for 5 h in X-Gal solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactosidase, 5 mM K 4 Fe(CN), 6 5 mM K 3 Fe(CN), 6 0.02% NP-40, 2 mM MgCl 2 in PBS). Where necessary, adjacent sections were stained with hematoxylin and eosin. For evaluating the proliferative capacity, cells were incubated with 50 mm BrdU (Sigma) for 1 h, washed, fixed in a 95% ethanol/5% (v/v) acetic acid solution for 20 min and then treated with 1.5 M HCl for 10 min. Immunofluorescent staining was carried out using the following antibodies: rabbit polyclonal 33 and mouse monoclonal (MF20) antibody to all sarcomeric MyCHs; mouse anti-BrdU (Amersham, Buckinghamshire, UK); mouse anti-Myogenin (F5D); rabbit antiArx, 13 Quantitative real-time polymerase chain reaction. Total cellular RNA was isolated from cell populations using RNeasy RNA isolation kit (Qiagen, Hilden, Germany). cDNAs were reverse transcribed from total RNA samples (100 ng/ sample) using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). TaqMan PCR reactions were carried out from cDNA samples using custom TaqMan low-density arrays (Applied Biosystems) by means of ABI PRISM 7900 HT Sequence Detection Systems. Gene expression profiling was achieved using the Comparative C T method of relative quantification. Until otherwise is not stated the ribosomal RNA 18 s subunit was used as an internal standard.
Transfection of C2C12 and MEFs. A BglII/EcoRI fragment containing the full-length human ARX cDNA was cloned into in pIres2-EGFP (Clontech, Mountain View, CA, USA), cut either with BglII/EcoRI or BamHI/EcoRI to generate phARXiresEGFP sense and antisense, respectively. C2C12 myoblasts were transfected using Lipofectamine with Plus reagent (Invitrogen, Carlsbad, CA, USA). Cytoplasmatic GFP-expressing cells were purified by FACS the day after transfection and then cultured in DMEM supplemented with 10% FCS under selection with G418. Efficient expression of the transgene was verified in stably transfected cells by FACS analysis for GFP and in the case of hARX cloned in the sense orientation (hARX sense), also by RT-PCR using a primer located in the ARX coding sequence and another in the IRES: (5 0 -CGGCATTCGGCAGGCTCT-3 0 ; 5 0 -AGGAACTGCTTCCTTCACGA-3 0 ). MEFs were isolated from Myf5 nlacZ/nlacZ (Mrf4):MyoD À/À E12.5 embryos. Cells were grown for six passages in DMEM supplemented with 20% FCS and transiently transfected with Lipofectamine with Plus reagent (Invitrogen). For the transfection, vectors encoding rat Myogenin, mouse MyoD, human MYF5 or MRF4 under the control of the Moloney murine sarcoma virus long terminal repeat (MoMSV-LTR) or an empty vector (pEMSV a-scribe) were used (provided by Dr. M Grossi). After transfection, cells were maintained either in DMEM with 10% FCS or 2% FCS for 2 days before RNA extraction.
For semiquantitative PCR, cDNA was reverse transcribed from total RNA with ThermoScript RT-PCR (Invitrogen), using random hexamers according to the manufacturer's instruction. The primers used to amplify Myosin light polypeptide 1 (Myl1) were 5 0 -GATCACCTTAAGTCAGGT-3 0 ; 5 0 -GCAAGGCTTCTACCTCTT-3 0 . Those used to amplify hMYF5 transcripts are 5 0 -GCCTTCTTCGTCCTGTGTATTA G-3 0 ; 5 0 -TGAGAGAGCAGGTGGAGAACTAC-3 0 . The other primers used have been published. 34, 35 All primers were designed to cross an intron/exon boundary. In the case of Arx amplification, 5% DMSO was added to the reaction mix.
CAT assay. CH310T1/2 fibroblasts were transiently transfected with Lipofectamine with Plus reagent (Invitrogen). Briefly, cells were seeded at 10 5 on 35 mm dishes and the following day, transfected alternatively with 0.5 mg of the reporter construct pMyo-1565CAT 36 or 4RCAT (containing the tk minimal promoter and four copies of the right E-boxes from the MCK enhancer 20 ) and 0.5 mg pCMVbGal (Clontech) alone or together with various combinations of plasmids mixed as follows: 1 mg of pEMSV a-scribe þ 0.5 mg pires2EGFP (control); 0.5 mg of pEMSVMyf3 (Myod1) þ 0.5 mg pires2EGFP þ 0.5 mg of pEMSV a-scribe; 0.5 mg phARXiresEGFPsense þ 1 mg of pEMSV a-scribe; 0.5 mg of pEMSVMyf3 þ 0.5 mg phARXiresEGFPsense þ 0.5 mg of pEMSV a-scribe; 0.5 mg of TAMef2C þ 0.5 mg pires2EGFP þ 0.5 mg of pEMSV a-scribe; 0.5 mg of TA-Mef2C þ 0.5 mg phARXiresEGFPsense þ 0.5 mg of pEMSV a-scribe and 0.5 mg of pEMSVMyf3 þ 0.5 mg pires2EGFP þ 0.5 mg of TA-Mef2C . TA-Mef2C was generated by inserting the murine Mef2C cDNA in the HindIII/XbaI sites of pFlag-CMV vector (Sigma). Cells were grown for 2 days in DMEM, 10% FCS and proteins were then extracted by repeated freezing-thawing. The levels of CAT protein were determined using an enzymatic immunoassay (CAT-ELISA/Roche). Cell extracts were normalized for protein concentration and CAT expression was further normalized to b-galactosidase activity.
Mutant animals and genotyping. The mutant and transgenic animals and genotyping primers used in this work were published: Pax3 GFP , 5 Arx nlacZ , 13 Tg: 3F-nlacZ-2E, 37 MyoD Whole-mount ISH and X-Gal staining. Whole-mount ISH was performed according to standard protocols. RNA probes labeled with digoxigenin-UTP (Roche) were synthesized from linearized cDNA templates according to manufacturer's instructions. A fragment corresponding to the full-length mouse Arx cDNA 34 and a 695-bp fragment corresponding to the 3 0 end of murine Myogenin cDNA were used as riboprobes. For whole-mount X-Gal staining, embryos and isolated muscles were fixed overnight in 4% paraformaldehyde at 41C and stained as described for the sections.
Immunoprecipitation and western blot. C2C12 myoblasts were transiently transfected with a vector encoding a Myc-tagged GFP-hARX fusion protein (Myc-ARX).
26 CH310T1/2 fibroblasts were transiently transfected with various combinations of plasmids mixed as follows: 1 mg of Myc-ARX þ 1 mg of TA-Mef2C; 1 mg of pEMSV-Myf3 (Myod1) þ 1 mg of TA-Mef2C or 1 mg of pEMSVMyf3 þ 1 mg of Myc-ARX. The immunoprecipitation assay was performed as described previously 40 by using mouse anti-Myc tag, (Roche), mouse anti-MyoD (Dako) or goat anti-Mef2C (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies. Immunoprecipitations with normal goat and mouse IgG (Santa Cruz) were used as controls.
For western blot analysis, immunoprecipitates and total extracts were resolved by SDS-PAGE on 10% polyacrylamide gels and then transferred onto nitrocellulose. After blocking in 5% milk in Tris-buffered saline (TBS)-T (TBS plus 0.02% Tween 20), filters were incubated with anti-MyoD, anti-Myogenin, mouse anti-Mef2C (Cell Signaling, Danvers, MA, USA) or mouse anti-tubulin (Covance, Princeton, NJ, USA) antibodies. After being washed, membranes were incubated with horseradish peroxidase-conjugated, species-specific secondary antibodies (Bio-Rad, Hercules, CA, USA) followed by enhanced chemiluminescence system (Amersham).
